Exela Technologies Reports Third Quarter 2017 Results
Third Quarter Revenue of
Third Quarter Further Adjusted EBITDA of
Affirms 2017 Financial Outlook and Tightens the
On-Track to Deliver Business Combination Savings
Announces Share Buyback Program of up to 5 Million Shares of Common Stock
“We are pleased with our third quarter results which include solid revenue and EBITDA growth and free cash flow generation. The integration of SourceHOV and Novitex is essentially complete, and we are on track to achieve our merger synergy targets. Our leading end-to-end solutions and deep domain expertise position us well to continue expanding with our current customers and grow our client base. In addition, our strong cash flow provides us with significant financial flexibility to continue to invest in organic and inorganic growth initiatives,” said
Financial information contained in this press release is presented Pro Forma for the previously announced business combination of
Third Quarter 2017 Pro Forma Financial Highlights
- Revenue: Total revenue for the quarter ended
September 30, 2017 was$358.2 million , an increase of 12.2% from$319.1 million in the third quarter of 2016, and an increase of 2.3% from$350.0 million in the second quarter of 2017. Information & Transaction Processing Solutions revenue was$279.8 million in the third quarter of 2017. Healthcare Solutions revenue was$56.4 million . Legal and Loss Prevention Services revenue was$22.0 million .
- Further AdjustedEBITDA: Further Adjusted EBITDA for the quarter ended
September 30, 2017 was$88.0 million , representing a Further Adjusted EBITDA margin of 24.6%, compared with Further Adjusted EBITDA of$80.0 million and 25.1% margin in the third quarter of 2016, and Further Adjusted EBITDA of$82.7 million and 23.6% margin in the second quarter of 2017.
- Net Loss: Net loss for the quarter ended
September 30, 2017 was($130.5) million compared with a net loss of($16.7) million in the prior year's third quarter and a net loss of$(27.9) million in the second quarter of 2017.
- Further AdjustedFree Cash Flow: Further Adjusted Free Cash Flow for the quarter ended
September 30, 2017 was$80.3 million , representing 91.2% of Further Adjusted EBITDA.
- Balance Sheet and Liquidity: At
September 30, 2017 , Exela’s total liquidity was approximately$124 million and total debt was approximately$1.41 billion . The Company had cash of$46.6 million , of which$19.2 million is segregated for customer use and a$100 million revolving credit facility, which was undrawn, but net of$22.8 million in stand-by letters of credit, giving the Company$77.2 million atSeptember 30, 2017 available for borrowing.
Financial Outlook for fiscal 2017
- Total revenue is expected to be in the range of
$1,450 million to $1,470 million . - Further Adjusted EBITDA is expected to be in the range of
$350 million to $370 million . - Further Adjusted Free Cash Flow is expected to be in the range of
$310 million to $320 million .
Share Buyback Program
On
Earnings Conference Call and Audio Webcast
About
About Non-GAAP Financial Measures: This earnings release presents non-GAAP financial measures including EBITDA, Adjusted EBITDA, Further Adjusted EBITDA, Free Cash Flow, and Further Adjusted Free Cash Flow, each of which is a financial measure that is not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The Company believes that these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company’s financial condition and results of operations. The Company does not consider these non-GAAP measures in isolation or as an alternative to liquidity or financial measures determined in accordance with GAAP. A limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures and therefore the basis of presentation for these measures may not be comparable to similarly-titled measures used by other companies. These non-GAAP measures should not be considered in isolation of, or as an alternative to, GAAP financial measures. For reconciliation of the comparable GAAP measures to these non-GAAP financial measures, see the schedules to this release. Optimization & restructuring expenses and merger adjustments are primarily related to the implementation of strategic actions and initiatives related to the business combination completed on
Forward-Looking Statements: Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, the estimated or anticipated future results and benefits of the recently consummated transaction between
Contact:
E: ir@exelatech.com
W: investors.exelatech.com
T: 646-277-1236
Exela Technologies, Inc. and Subsidiaries Schedule 1: Pro Forma Q3 2016 vs. Q3 2017 Financial Performance (In millions of United States dollars) |
|||||
($ in millions) |
Pro Forma Q3 2016(1) |
Pro Forma Q3 2017 |
% Change | ||
Revenue | |||||
Information and Transaction Processing Solutions | $230.2 | $279.8 | |||
Healthcare Solutions | 60.7 | 56.4 | |||
Legal and Loss Prevention Services | 28.3 | 22.0 | |||
Total Revenue | $319.1 | $358.2 | 12.2% | ||
Cost of Revenue (excluding D&A) | $229.7 | $271.1 | |||
Gross Profit | $89.5 | $87.1 | |||
Gross Margin | 28.0% | 24.3% | |||
SG&A (excluding D&A) | $41.5 | $106.5 | |||
Further Adjusted EBITDA(2) | $80.0 | $88.0 | 10.0% | ||
% Margin | 25.1% | 24.6% | |||
(1) Financial results for Pro Forma Q3 2016 do not include contribution from the TransCentra acquisition which closed on
(2)For additional information refer to Further Adjusted EBITDA Reconciliations.
Exela Technologies, Inc. and Subsidiaries Schedule 2: Pro Forma YTD Q3 2016 vs. YTD Q3 2017 Financial Performance (In millions of United States dollars) |
|||||
($ in millions) |
Pro Forma YTD Q3 2016(1) |
Pro Forma YTD Q3 2017 |
% Change | ||
Revenue | |||||
Information and Transaction Processing Solutions | $712.2 | $829.5 | |||
Healthcare Solutions | 189.0 | 173.5 | |||
Legal and Loss Prevention Services | 79.4 | 66.9 | |||
Total Revenue | $980.6 | $1,070.0 | 9.1% | ||
Cost of Revenue (excluding D&A) | $701.1 | $790.0 | |||
Gross Profit | $279.5 | $280.0 | |||
Gross Margin | 28.5% | 26.2% | |||
SG&A (excluding D&A) | $133.4 | $207.4 | |||
Further Adjusted EBITDA(2) | $265.9 | $269.3 | 1.3% | ||
% Margin | 27.1% | 25.2% | |||
(1) Financial results for Pro Forma YTD Q3 2016 do not include contribution from the TransCentra acquisition which closed on
(2) For additional information refer to Further Adjusted EBITDA Reconciliations.
Exela Technologies, Inc. and Subsidiaries Schedule 3: Further Adjusted EBITDA Reconciliation – Q3 2016 (In millions of United States dollars) |
|||||||
($ in millions) | As Reported Q3 2016(1) |
Novitex Q3 2016 |
Pro Forma Q3 2016(1) |
||||
Net loss | ($11.8) | ($4.9) | ($16.7) | ||||
Taxes | (3.8) | (3.3) | (7.1) | ||||
Interest expense | 27.4 | 12.2 | 39.6 | ||||
Depreciation and amortization | 18.8 | 10.3 | 29.1 | ||||
EBITDA | $30.6 | $14.2 | $44.8 | ||||
Loss on extinguishment of debt | - | - | - | ||||
Optimization and restructuring expenses | 4.9 | (0.2) | 4.7 | ||||
Transaction and integration costs | 0.7 | - | 0.7 | ||||
Non-cash charges | 1.8 | - | 1.8 | ||||
New contract setup | - | 2.0 | 2.0 | ||||
Oversight and management fee | 1.7 | 0.4 | 2.1 | ||||
Adjusted EBITDA | $39.8 | $16.4 | $56.3 | ||||
Foreign exchange gains / losses | 0.7 | - | 0.7 | ||||
Combined merger adjustments | 23.0 | ||||||
Further Adjusted EBITDA | $80.0 | ||||||
(1) Financial results as reported for Q3 2016 and Pro Forma Q3 2016 do not include contribution from the TransCentra acquisition which closed on
Exela Technologies, Inc. and Subsidiaries Schedule 4: Further Adjusted EBITDA Reconciliation – Q3 2017 (In millions of United States dollars) |
|||||||
($ in millions) | As Reported Q3 2017 |
Novitex (Jul 1 – Jul 12)(1) |
Pro Forma Q3 2017 |
||||
Net loss | ($110.4) | ($20.1) | ($130.5) | ||||
Taxes | (37.0) | 0.0 | (37.0) | ||||
Interest expense | 37.7 | 0.6 | 38.3 | ||||
Depreciation and amortization | 28.1 | 1.2 | 29.2 | ||||
EBITDA | ($81.7) | ($18.2) | ($100.0) | ||||
Loss on extinguishment of debt | 35.5 | 17.5 | 53.0 | ||||
Optimization and restructuring expenses | 19.7 | 1.2 | 20.9 | ||||
Transaction and integration costs | 77.3 | 2.0 | 79.3 | ||||
Non-cash charges | 2.3 | - | 2.3 | ||||
New contract setup | - | - | - | ||||
Oversight and management fee | (0.0) | 0.1 | 0.0 | ||||
Adjusted EBITDA | $53.0 | $2.5 | $55.5 | ||||
Foreign exchange gains / losses | 0.7 | - | 0.7 | ||||
Combined merger adjustments | 31.8 | ||||||
Further Adjusted EBITDA | $88.0 | ||||||
(1) Represents financial performance of Novitex for a 12 day period prior to the transaction closing date of
Exela Technologies, Inc. and Subsidiaries Schedule 5: Further Adjusted EBITDA Reconciliation – YTD Q3 2016 (In millions of United States dollars) |
||||||
($ in millions) | ||||||
As Reported YTD Q3 2016(1) |
Novitex YTD Q3 2016 |
Pro Forma YTD Q3 2016(1) |
||||
Net loss | ($33.4) | ($13.9) | ($47.3) | |||
Taxes | (10.0) | (8.3) | (18.2) | |||
Interest expense | 81.7 | 35.4 | 117.1 | |||
Depreciation and amortization | 58.5 | 30.6 | 89.1 | |||
EBITDA | $96.8 | $43.9 | $140.6 | |||
Gain on extinguishment of debt | - | (2.3) | (2.3) | |||
Optimization and restructuring expenses | 14.4 | 11.5 | 25.9 | |||
Transaction and integration costs | 1.9 | (0.1) | 1.8 | |||
Non-cash charges | 6.9 | 0.1 | 7.0 | |||
New contract setup | - | 4.4 | 4.4 | |||
Oversight and management fee | 5.4 | 0.9 | 6.3 | |||
Adjusted EBITDA | $125.4 | $58.4 | $183.8 | |||
Foreign exchange gains / losses | 0.3 | - | 0.3 | |||
Combined merger adjustments | 81.9 | |||||
Further Adjusted EBITDA | $265.9 | |||||
(1) Financial results as reported for YTD Q3 2016 and Pro Forma YTD Q3 2016 do not include contribution from the TransCentra acquisition which closed on
Exela Technologies, Inc. and Subsidiaries Schedule 6: Further Adjusted EBITDA Reconciliation – YTD Q3 2017 (In millions of United States dollars) |
||||||
($ in millions) | ||||||
As Reported YTD Q3 2017 |
Novitex (Jan 1 – Jul 12)(1) |
Pro Forma YTD Q3 2017 |
||||
Net loss | ($145.6) | ($38.1) | ($183.8) | |||
Taxes | (32.9) | (6.9 | (39.9) | |||
Interest expense | 91.7 | 24.9 | 116.7 | |||
Depreciation and amortization | 70.8 | 20.6 | 91.4 | |||
EBITDA | ($16.0) | $0.5 | ($15.5) | |||
Loss on extinguishment of debt | 35.5 | 17.5 | 53.0 | |||
Optimization and restructuring expenses | 31.5 | 5.4 | 36.9 | |||
Transaction and integration costs | 86.6 | 10.0 | 96.6 | |||
Non-cash charges | 4.4 | - | 4.4 | |||
New contract setup | - | 2.0 | 2.0 | |||
Oversight and management fee | 4.1 | 1.0 | 5.1 | |||
Adjusted EBITDA | $146.1 | $36.4 | $182.5 | |||
Foreign exchange gains / losses | 3.0 | 0.1 | 3.1 | |||
Combined merger adjustments | 83.7 | |||||
Further Adjusted EBITDA | $269.3 | |||||
(1) Represents financial performance of Novitex for a year-to-date period ending on the transaction closing date of
Source: Exela Technologies, Inc.